EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio
· Financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors · Proceeds will support the Phase 1/2 clinical development of lead program SB-007 in Stargardt disease, a genetic eye disorder that causes progressive vision loss and blindness · Funding will also advance a broader pipeline of genetic medicines targeting indications in ophthalmology, neurology, and other therapeutic areasEQT Life Sciences is pleased to announce that the LSP 7 fund has invested in SpliceBio. The Spanish biotech company is